News & Trends - Medical Technology

Medtronic’s landmark trial shows superiority for renal denervation in patients with high blood pressure

Health Industry Hub | March 31, 2020 |
[Total: 1    Average: 4/5]

MedTech News: Medtronic announced first-ever clinical data from the SPYRAL HTN-OFF MED Pivotal Trial. The trial was designed to assess the efficacy of renal denervation in the absence of antihypertensive medications.

The study met its primary and secondary effectiveness endpoints, with a >99.9% probability of superiority for both versus those who received a sham control procedure (control arm). Additionally, there were no major device or procedural safety events through three months.

The study was presented on 30th March as part of the American College of Cardiology together with the World Congress of Cardiology Scientific Sessions (ACC.20/WCC) and published simultaneously in The Lancet.

The global, sham-controlled study evaluated 331 patients—166 of whom were randomised to renal denervation (RDN), a minimally invasive procedure intended to regulate overactivity of nerves that lead to and from the kidney.

Register FREE and join 20,000+ industry professionals receiving the latest industry news and engaging content from Health Industry Hub; the ONLY one-stop-hub connecting Australia’s Pharma, MedTech and Biotech industry professionals.

Results showed a statistically significant 9.2 mm Hg reduction in patients’ office systolic blood pressure (OSBP) and 4.7 mm Hg reduction in 24-hour systolic ambulatory blood pressure (ABPM) at three months in those treated with the Symplicity Spyral RDN system.

A Victorian grandmother was the first patient in the world to receive renal denervation in 2007, under the care of Professor Murray Esler, a clinical cardiologist and medical scientist, based at the Baker Heart and Diabetes Institute and the Alfred Hospital in Melbourne.

“These results demonstrated outstanding safety, with zero procedural and device major adverse events through three months, and no worsening of kidney function. In previous research, blood pressure reduction of the magnitude observed here has been associated with a 20% reduction in relative risk of cardiovascular events,” Professor Esler said. “It is anticipated that the blood pressure lowering and safety demonstrated in this pivot trial will now lead to greater world-wide use of RDN in the treatment of hypertension, including in Australia.”

Customer engagement during COVID-19. Fill the gap of reduced fieldforce activities. Health Industry Hub combines expertise in delivering digital health content and measuring engagement with 20+ years industry experience. Created by industry for industry. Contact us.

“As many patients with uncontrolled hypertension struggle to adhere to lifelong drug therapy for a variety of reasons and may look to other options that complement traditional treatments, we believe this advance could help clinicians work with patients to better manage their high blood pressure,” said Dave Moeller, vice president and general manager of the Coronary and Renal Denervation business at Medtronic.

High blood pressure is the most common of all the conditions of the circulatory system. One in four Australians have hypertension, with around 4 million adults had uncontrolled or unmanaged high blood pressure (not taking medication).

The annual direct costs of hypertension are estimated at approximately AU$694 billion worldwide. It is estimated that almost 20 percent of patients with uncontrolled hypertension are completely non-adherent to oral medications, while nearly half are partially non-adherent, highlighting the need for alternative treatment options.

The Symplicity Spyral system is approved for commercial use in more than 60 countries around the world including Australia and New Zealand.

You may also like Private hospital capacity to fight coronavirus lost unless states move quickly on agreement


About the author

About the author

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nam luctus finibus scelerisque. Nunc bibendum ipsum sed augue fringilla fringilla. Nullam at consectetur leo. Praesent viverra rutrum porta. Quisque vitae mi vel purus vulputate tincidunt. Class aptent taciti sociosqu ad litora torquent per conubia nostra, per inceptos himenaeos. Suspendisse et mi quis nisi rhoncus feugiat at ac tellus. Sed aliquam sodales nulla ac auctor. Sed pretium lobortis purus accumsan ullamcorper. Phasellus sodales vel odio in lobortis. Duis maximus sagittis bibendum. Interdum et malesuada fames ac ante ipsum primis in faucibus. Nunc dictum tincidunt ipsum in vestibulum. Donec ut sem consectetur, aliquam quam vitae, pharetra orci. Nam egestas non velit eu rhoncus. Duis congue neque non lacus tincidunt porta. Vestibulum ultricies pulvinar sem, molestie congue dui aliquet non.
  • Ut imperdiet leo id lorem fermentum consectetur.
  • Ut vitae orci et dui varius tincidunt.
  • Ut id magna non libero vestibulum pharetra ac faucibus nulla.
Aliquam erat volutpat. Vestibulum vitae varius diam. Nulla eget congue ante. Nunc ullamcorper sagittis augue vel dictum. Mauris finibus nibh ut pulvinar auctor. Vestibulum ut faucibus nisi. Orci varius natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Quisque porta tortor ac justo malesuada elementum. Nulla tellus ante, cursus nec ex sit amet, suscipit bibendum arcu. Duis posuere orci dui, et mollis enim dictum at. Sed ullamcorper, sapien ut vulputate viverra, sem purus porttitor tellus, nec mattis mauris ligula sed risus. Nulla sagittis id ipsum eu mattis. Link to full profile

News & Trends - Pharmaceuticals

Pharma News - 20 biopharmaceutical companies enter a ground-breaking partnership - AMR Action Fund

20 biopharmaceutical companies enter a ground-breaking partnership

Health Industry Hub | July 10, 2020 |

Please log in to Health Industry Hub to view this content in the ‘News & Trends’ menu.

Health Industry Hub is Australia’s ONLY one-stop-hub connecting Pharma, Biotech and MedTech industry professionals. Learn more.

More


Market Research & Insights

Market Research Pharma Biotech MedTech - Incredible breadth of Australia’s COVID-19 research: From vaccines to aircon filters

Incredible breadth of Australia’s COVID-19 research: From vaccines to aircon filters

Health Industry Hub | July 9, 2020 |

Market Research & Insights: Since the coronavirus hit Australia’s shores, health and medical researchers have been rapidly redeployed in unprecedented […]

More


Mentoring

Pharma Biotech Medtech Mentoring - Award-winning IMNIS program fosters collaboration and innovation between industry and academia

Award-winning IMNIS program fosters collaboration and innovation between industry and academia

Health Industry Hub | July 9, 2020 |

Mentoring: The Industry Mentoring Network in STEM (IMNIS) provides PhD student mentees an understanding of the industry sector, strengthen their […]

More


Communication

Communication Public Relations Pharma Biotech Medtech - The changing landscape of Pharma corporate communications - interview

The changing landscape of corporate communications in the Pharma industry

Health Industry Hub | July 8, 2020 |

COVID-19 has had a dramatic impact on the role and nature of healthcare communications, especially following the recent bushfire crisis […]

More